ImmunityBio, Inc.
ImmunityBio, Inc. (NASDAQ: IMNB) is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system to deliver durable protection against cancer and infectious diseases. The company's website is www.immunitybio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ImmunityBio, Inc. does
In the company’s own words
ImmunityBio, Inc. (NASDAQ: IMNB) is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system to deliver durable protection against cancer and infectious diseases. The company's website is www.immunitybio.com.
The company's core strategy centers on the Cancer BioShield platform, a comprehensive immunotherapy approach designed to stimulate critical lymphocytes including natural killer cells, cytotoxic T cells, and memory T cells. The platform is anchored by ANKTIVA, a first-in-class IL-15 receptor superagonist antibody-cytokine fusion protein that represents the company's lead approved biologic product.
ANKTIVA received FDA approval in April 2024 for the treatment of BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors. The product has subsequently received regulatory approvals in the United Kingdom, Saudi Arabia, and the European Union. In Saudi Arabia, ANKTIVA also received conditional approval for use in combination with checkpoint inhibitors for metastatic non-small cell lung cancer. The company began commercial distribution of ANKTIVA in May 2024 and generated approximately $113 million in net product revenue during 2025, representing approximately 700 percent year-over-year growth. Payer coverage for ANKTIVA exceeds 240 million lives in the United States as of December 2025.
Beyond ANKTIVA, ImmunityBio's Cancer BioShield platform encompasses multiple therapeutic modalities including adenovirus-vectored vaccines targeting tumor-associated antigens and neoepitopes, off-the-shelf targeted chimeric antigen receptor natural killer cell therapies, and memory-like cytokine-enhanced natural killer cells. The company is advancing several product candidates across oncology indications including glioblastoma, pancreatic cancer, non-Hodgkin lymphoma, and various solid tumors, with multiple programs receiving FDA designations including Breakthrough Therapy and Regenerative Medicine Advanced Therapy status.
ImmunityBio operates manufacturing facilities and maintains global partnerships to support the development and commercialization of its therapeutic portfolio. The company has established commercial partnerships with international healthcare providers to expand ANKTIVA's global reach and accessibility.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1326110
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ImmunityBio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ImmunityBio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ImmunityBio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ImmunityBio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ImmunityBio, Inc.'s last four quarterly filings that the numbers alone won't show?”